IMCR: Immunocore PLC Net earnings per share (EPS TTM)

Immunocore (IMCR) - corporate logo

Immunocore Holdings plc (IMCR) success is based on the global sales of Kimmtrak and the effectiveness of its TCR pipeline. The profit per unit trend over the last 12 months illustrates financial stability, while the -0.62 value reflects the metric's balance. The reduction of risk concentration is being achieved through the development of lung cancer therapy. However, dependence on a single product and potential side effects pose a threat to its market positions.

IMCR Immunocore Holdings plc Net earnings per share for the last 12 months (07/04/2022 - 11/18/2026)

Summary analytical data breakdowns for Immunocore Corp (IMCR)

- share price and expert price forecast:
Fundamental valuation:IMCR - Immunocore Corp
Flagship merchandise of Immunocore PLC

Immunocore Holdings plc (IMCR) is strengthening its position in cancer immunotherapy through synergies with pharmaceutical behemoths, which directly impacts the efficiency of the ImmTAX platform. By analyzing the net income per share trend, an investor assesses the final annual financial result adjusted for issuance volume, allowing for the verification of the business's actual resilience and the determination of the asset's long-term growth potential.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year JANX (Janux Therapeutics, Inc.)|RCUS: Net earnings per share (EPS TTM)|ZYME - Net earnings per share for the last four quarters|Earnings per share for the last twelve months tangotx.com|Net earnings per share for the last 12 months iovance.com (IOVA)|Earnings per share for the last twelve months Immatics NV (IMTX)|Net earnings per share for the last 12 months Xencor Corp XNCR|Compass Therapeutics Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Replimune Inc. REPL|LYEL - Earnings per share for the last twelve months|IPHA (innate-pharma.com) - Earnings per share for the last 12 months|pyxisoncology.com (PYXS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Compugen Ltd. (CGEN)|Net earnings per share for the last 12 months IOBT|STRO - Net earnings per share for the trailing year|Net earnings per share for the last 12 months INKT (MiNK)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma, Inc.)|Earnings per share for the trailing year ALXO|CUE - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)